Reply to Tan et al.
作者信息
Kuhar David T, Struble Kimberly A, Henderson David K
机构信息
Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
出版信息
Infect Control Hosp Epidemiol. 2014 Mar;35(3):328-9. doi: 10.1086/675350.
Abstract
摘要
相似文献
1
Reply to Tan et al.对谭等人的回复
Infect Control Hosp Epidemiol. 2014 Mar;35(3):328-9. doi: 10.1086/675350.
2
Selecting an antiretroviral regimen for human immunodeficiency virus postexposure prophylaxis in the occupational setting.在职业暴露情况下为预防人类免疫缺陷病毒选择抗逆转录病毒治疗方案。
Infect Control Hosp Epidemiol. 2014 Mar;35(3):326-8. doi: 10.1086/675297.
3
Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis.美国更新的公共卫生服务指南，用于管理职业暴露于人类免疫缺陷病毒和暴露后预防建议。
Infect Control Hosp Epidemiol. 2013 Sep;34(9):875-92. doi: 10.1086/672271.
4
The Danish PEP Registry: Experience with the use of post-exposure prophylaxis following blood exposure to HIV from 1999-2012.丹麦 PEP 登记处：1999-2012 年期间，针对因血液接触 HIV 而进行暴露后预防的使用经验。
Infect Dis (Lond). 2016;48(3):195-200. doi: 10.3109/23744235.2015.1103896. Epub 2015 Nov 3.
5
Revised guidelines for occupational HIV exposure include simpler regimens.
Am J Health Syst Pharm. 2013 Oct 1;70(19):1642, 1246. doi: 10.2146/news130067.
6
Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers).人类免疫缺陷病毒与艾滋病的预防：暴露后预防（包括医护人员）
Infect Dis Clin North Am. 2014 Dec;28(4):601-13. doi: 10.1016/j.idc.2014.08.005. Epub 2014 Oct 5.
7
Policies for exposure to bloodborne pathogens among US-based international voluntary medical organizations.美国国际志愿医疗组织中血源性病原体暴露的相关政策。
JAMA. 2002 Jul 10;288(2):166. doi: 10.1001/jama.288.2.166.
8
Human immunodeficiency virus postexposure prophylaxis for medical trainees on international rotations.国际轮转实习医学生的人类免疫缺陷病毒暴露后预防
J Travel Med. 2010 Jul-Aug;17(4):264-8. doi: 10.1111/j.1708-8305.2010.00421.x.
9
Prevention and management of occupational exposures to human immunodeficiency virus (HIV).职业性接触人类免疫缺陷病毒（HIV）的预防与管理。
Mt Sinai J Med. 2006 Oct;73(6):852-6.
10
Occupational Health Update: Focus on Preventing the Acquisition of Infections with Pre-exposure Prophylaxis and Postexposure Prophylaxis.职业健康最新资讯：聚焦于通过暴露前预防和暴露后预防来预防感染的获得。
Infect Dis Clin North Am. 2016 Sep;30(3):729-57. doi: 10.1016/j.idc.2016.04.008.
引用本文的文献
1
Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers).人类免疫缺陷病毒与艾滋病的预防：暴露后预防（包括医护人员）
Infect Dis Clin North Am. 2014 Dec;28(4):601-13. doi: 10.1016/j.idc.2014.08.005. Epub 2014 Oct 5.
本文引用的文献
1
Selecting an antiretroviral regimen for human immunodeficiency virus postexposure prophylaxis in the occupational setting.在职业暴露情况下为预防人类免疫缺陷病毒选择抗逆转录病毒治疗方案。
Infect Control Hosp Epidemiol. 2014 Mar;35(3):326-8. doi: 10.1086/675297.
2
Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.拉替拉韦/恩曲他滨/替诺福韦用于男男性行为人群 HIV 非职业暴露后预防的安全性、耐受性和依从性。
HIV Med. 2014 Jan;15(1):13-22. doi: 10.1111/hiv.12075. Epub 2013 Sep 6.
3
Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis.美国更新的公共卫生服务指南，用于管理职业暴露于人类免疫缺陷病毒和暴露后预防建议。
Infect Control Hosp Epidemiol. 2013 Sep;34(9):875-92. doi: 10.1086/672271.
4
Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.拉替拉韦、替诺福韦酯和恩曲他滨用于暴露后预防以防止 HIV 的性传播：安全性、耐受性和依从性。
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):354-9. doi: 10.1097/QAI.0b013e31824a03b8.
5
Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.替诺福韦/恩曲他滨和洛匹那韦/利托那韦片剂制剂用于 HIV 暴露后预防的耐受性。
AIDS. 2010 Sep 24;24(15):2375-80. doi: 10.1097/QAD.0b013e32833dfad1.
Zotero 插件